• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 3. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 4. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

Introduction to [2,2]Bipiperidinyl-6-one (CAS No. 1378260-14-0)

[2,2]Bipiperidinyl-6-one is a significant compound in the field of pharmaceutical chemistry, known for its unique structural and functional properties. This compound, identified by the CAS number 1378260-14-0, has garnered considerable attention due to its potential applications in drug development and medicinal chemistry. The molecular structure of [2,2]Bipiperidinyl-6-one consists of a bipiperidinyl core, which is a fused system of two piperidine rings, linked by a carbonyl group at the sixth position. This distinctive arrangement imparts remarkable chemical reactivity and versatility, making it a valuable scaffold for synthesizing various bioactive molecules.

The compound's bipiperidinyl moiety is particularly noteworthy, as it serves as a privileged structure in medicinal chemistry. Piperidine derivatives are widely recognized for their role in pharmaceuticals, often acting as key pharmacophores in drugs targeting neurological and cardiovascular diseases. The presence of two piperidine rings in [2,2]Bipiperidinyl-6-one enhances its binding affinity and selectivity, which are critical factors in drug design. Recent studies have highlighted its utility in developing novel therapeutic agents that interact with specific biological targets.

One of the most compelling aspects of [2,2]Bipiperidinyl-6-one is its role as a precursor in the synthesis of more complex molecules. Researchers have leveraged its structural features to create derivatives with enhanced pharmacological properties. For instance, modifications at the carbonyl group or the piperidine rings have led to compounds with improved solubility, bioavailability, and metabolic stability. These advancements underscore the importance of [2,2]Bipiperidinyl-6-one in the arsenal of synthetic chemists working on next-generation therapeutics.

In recent years, [2,2]Bipiperidinyl-6-one has been explored in the context of central nervous system (CNS) drug discovery. Its bipiperidinyl core exhibits properties that make it an attractive candidate for developing treatments for neurological disorders such as Parkinson's disease and Alzheimer's disease. The compound's ability to cross the blood-brain barrier and interact with neurotransmitter receptors has been a focal point of investigation. Preliminary findings suggest that derivatives of [2,2]Bipiperidinyl-6-one may offer novel mechanisms of action that could address unmet medical needs.

The synthesis of [2,2]Bipiperidinyl-6-one involves multi-step organic reactions that highlight its synthetic accessibility despite its complex structure. Modern synthetic methodologies have enabled efficient production routes, allowing researchers to explore its derivatives without significant hurdles. The compound's reactivity at the carbonyl group and the piperidine rings provides multiple avenues for functionalization, making it a versatile building block in medicinal chemistry.

From a computational chemistry perspective, [2,2]Bipiperidinyl-6-one has been subjected to extensive molecular modeling studies. These studies aim to elucidate its interactions with biological targets at an atomic level. By understanding its binding modes and energetics, scientists can optimize its pharmacological properties further. Advanced computational techniques have revealed insights into how structural modifications can fine-tune its activity against specific disease-related proteins.

The future prospects of [2,2]Bipiperidinyl-6-one are promising, with ongoing research focusing on expanding its applications in drug discovery. Collaborative efforts between academic institutions and pharmaceutical companies are expected to yield innovative derivatives with enhanced therapeutic potential. The compound's unique structural features continue to inspire new synthetic strategies and functionalizations that could lead to breakthroughs in treating various human diseases.

In conclusion, [2,2]Bipiperidinyl-6-one (CAS No. 1378260-14-0) stands out as a pivotal compound in pharmaceutical chemistry due to its versatile structure and broad applicability. Its role as a scaffold for developing novel bioactive molecules has been well-documented in recent research. As the field of medicinal chemistry progresses, [2,2]Bipiperidinyl-6-one is poised to play an increasingly significant role in addressing complex medical challenges through innovative drug design and development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)